Surface Oncology to Participate in Upcoming Investor Conferences
May 17 2022 - 4:30PM
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology
company developing next-generation immunotherapies that target the
tumor microenvironment, today announced that Rob Ross, M.D., chief
executive officer, will participate in two upcoming investor
conferences:
- A fireside chat at the UBS Global Healthcare Conference on
Monday, May 23, 2022, at 2:45 p.m. ET in New York City.
- A corporate presentation at the H.C. Wainwright Global
Investment Conference. The prerecorded presentation will become
available on-demand starting Tuesday, May 24, 2022, at 7 a.m.
ET.
Archived webcasts of the fireside chat and
on-demand corporate presentation will be accessible from the Events
& Presentations page of the company's website.
About Surface OncologySurface
Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment. Its pipeline includes two wholly-owned
clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388),
as well as a preclinical program focused on selectively depleting
regulatory T cells in the tumor microenvironment via targeting CCR8
(SRF114). In addition, Surface has two partnerships with major
pharmaceutical companies: a collaboration with Novartis targeting
CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline
targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s
novel, investigational cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. For
more information, please visit www.surfaceoncology.com.
ContactScott Young(617)
865-3250syoung@surfaceoncology.com
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Apr 2023 to Apr 2024